Cyclin-Dependent Kinase Inhibitor P1446A Induces Apoptosis in a JNK/p38 MAPK-Dependent Manner in Chronic Lymphocytic Leukemia B-Cells
暂无分享,去创建一个
Jennifer R. Brown | S. Spurgeon | A. Danilov | Sreesha P. Srinivasa | J. C. Godbersen | C. Paiva | R. Soderquist | T. Rowland | Sumner Kilmarx | Cody Paiva
[1] A. Eastman,et al. Vincristine activates c-Jun N-terminal kinase in chronic lymphocytic leukaemia in vivo. , 2015, British journal of clinical pharmacology.
[2] Jeffrey A Jones,et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. , 2015, Blood.
[3] Jeffrey A Jones,et al. Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia , 2015, Leukemia.
[4] G. Packham,et al. Stimulation of surface IgM of chronic lymphocytic leukemia cells induces an unfolded protein response dependent on BTK and SYK. , 2014, Blood.
[5] Jennifer R. Brown,et al. A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53 , 2014, British journal of haematology.
[6] Daniel P. Denning,et al. Anti-tubulins DEPendably induce apoptosis , 2014, Nature Cell Biology.
[7] M. Hengartner,et al. DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis , 2014, Nature Cell Biology.
[8] J. Byrd,et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. , 2014, The New England journal of medicine.
[9] T. Kawauchi. Cdk5 regulates multiple cellular events in neural development, function and disease , 2014, Development, growth & differentiation.
[10] J. Byrd,et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. , 2014, Cancer research.
[11] A. Eastman,et al. The Nedd8-Activating Enzyme Inhibitor MLN4924 Thwarts Microenvironment-Driven NF-κB Activation and Induces Apoptosis in Chronic Lymphocytic Leukemia B Cells , 2014, Clinical Cancer Research.
[12] Jeffrey A Jones,et al. How will B-cell-receptor-targeted therapies change future CLL therapy? , 2014, Blood.
[13] Allan Wu,et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. , 2014, Blood.
[14] S. Nekhai,et al. Regulation of CDK9 Activity by Phosphorylation and Dephosphorylation , 2014, BioMed research international.
[15] C. Fegan,et al. A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine , 2013, Oncotarget.
[16] John Calvin Reed,et al. ER stress-induced cell death mechanisms. , 2013, Biochimica et biophysica acta.
[17] B. Christensen,et al. Pro‐apoptotic TP53 homolog TAp63 is repressed via epigenetic silencing and B‐cell receptor signalling in chronic lymphocytic leukaemia , 2013, British journal of haematology.
[18] Jennifer R. Brown,et al. A Novel Cyclin Dependent Kinase Inhibitor P1446A Induces Apoptosis Of Chronic Lymphocytic Leukemia B Cells , 2013 .
[19] A. Eastman,et al. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo , 2013, Leukemia.
[20] A. Eastman,et al. Toward a cure for chronic lymphocytic leukemia: an attack on multiple fronts , 2013, Expert review of anticancer therapy.
[21] A. Eastman,et al. Vinblastine Rapidly Induces NOXA and Acutely Sensitizes Primary Chronic Lymphocytic Leukemia Cells to ABT-737 , 2013, Molecular Cancer Therapeutics.
[22] K. Sabapathy,et al. Oppositional Regulation of Noxa by JNK1 and JNK2 during Apoptosis Induced by Proteasomal Inhibitors , 2013, PloS one.
[23] L. Meijer,et al. Inhibition of NF-κB–Mediated Signaling by the Cyclin-Dependent Kinase Inhibitor CR8 Overcomes Prosurvival Stimuli to Induce Apoptosis in Chronic Lymphocytic Leukemia Cells , 2013, Clinical Cancer Research.
[24] S. M. Rubin. Deciphering the retinoblastoma protein phosphorylation code. , 2013, Trends in biochemical sciences.
[25] R. Fisher. The CDK Network: Linking Cycles of Cell Division and Gene Expression. , 2012, Genes & cancer.
[26] W. Wilson,et al. Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia. , 2012, Blood.
[27] Jeffrey A Jones,et al. ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol. , 2012, Blood.
[28] Jeffrey A Jones,et al. The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells , 2012, Leukemia.
[29] S. Nag,et al. A phase I study of selective cyclin dependent kinase inhibitor P1446A-05 administered on an intermittent schedule in patients with advanced refractory tumors. , 2012 .
[30] A. Oza,et al. A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor. , 2012 .
[31] K. Joshi,et al. Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity , 2012 .
[32] F. Dick,et al. The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle , 2012, Cell Division.
[33] P. Fischer,et al. CDKI‐71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol , 2012, International journal of cancer.
[34] C. Hetz. The unfolded protein response: controlling cell fate decisions under ER stress and beyond , 2012, Nature Reviews Molecular Cell Biology.
[35] John A. Hammer,et al. Walking to work: roles for class V myosins as cargo transporters , 2011, Nature Reviews Molecular Cell Biology.
[36] R. Jemmerson,et al. The proapoptotic function of Noxa in human leukemia cells is regulated by the kinase Cdk5 and by glucose. , 2010, Molecules and Cells.
[37] E. Lees,et al. Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.
[38] Nam‐Gyun Kim,et al. Regulation of protein stability by GSK3 mediated phosphorylation , 2009, Cell cycle.
[39] Jeffrey A Jones,et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] Hyoung-Gon Lee,et al. Direct and indirect roles of cyclin-dependent kinase 5 as an upstream regulator in the c-Jun NH2-terminal kinase cascade: relevance to neurotoxic insults in Alzheimer's disease. , 2009, Molecular biology of the cell.
[41] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[42] Jia Luo,et al. Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.
[43] Lisa S. Chen,et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.
[44] Peter M Fischer,et al. Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.
[45] H. Brenner,et al. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. , 2008, Blood.
[46] E. Estey. "Fairest of them all" for myelodysplastic syndromes , 2008 .
[47] Yulia Katsman,et al. B cell proliferation following CD40 stimulation results in the expression and activation of Src protein tyrosine kinase. , 2006, International immunology.
[48] R. Fisher. Secrets of a double agent: CDK7 in cell-cycle control and transcription , 2005, Journal of Cell Science.
[49] J. Inoue,et al. Recruitment of Tumor Necrosis Factor Receptor-associated Factor Family Proteins to Apoptosis Signal-regulating Kinase 1 Signalosome Is Essential for Oxidative Stress-induced Cell Death* , 2005, Journal of Biological Chemistry.
[50] W. Plunkett,et al. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. , 2005, Blood.
[51] P. Kaldis,et al. Cdc2–cyclin E complexes regulate the G1/S phase transition , 2005, Nature Cell Biology.
[52] Marc K Hellerstein,et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. , 2005, The Journal of clinical investigation.
[53] C. Peschel,et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells , 2004, Leukemia.
[54] Kiyoshi Inoue,et al. ASK1 is essential for endoplasmic reticulum stress-induced neuronal cell death triggered by expanded polyglutamine repeats. , 2002, Genes & development.
[55] D. Price,et al. Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.
[56] T Takahashi,et al. ASK1 is required for sustained activations of JNK/p38 MAP kinases and apoptosis , 2001, EMBO reports.
[57] John Calvin Reed,et al. Protein Kinase Inhibitors Flavopiridol and 7-hydroxy-staurosporine Down-regulate Antiapoptosis Proteins in B-cell Chronic Lymphocytic Leukemia , 2022 .
[58] Hong Liu,et al. Activation of Apoptosis Signal-Regulating Kinase 1 (ASK1) by Tumor Necrosis Factor Receptor-Associated Factor 2 Requires Prior Dissociation of the ASK1 Inhibitor Thioredoxin , 2000, Molecular and Cellular Biology.
[59] F. Urano,et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. , 2000, Science.
[60] M. Grever,et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. , 1998, Blood.
[61] L. Tsai,et al. p35, the Neuronal-specific Activator of Cyclin-dependent Kinase 5 (Cdk5) Is Degraded by the Ubiquitin-Proteasome Pathway* , 1998, The Journal of Biological Chemistry.
[62] S. Mittnacht,et al. Control of pRB phosphorylation. , 1998, Current opinion in genetics & development.